JAZZ
HEALTHCAREJazz Pharmaceuticals plc
$228.57+16.31 (+7.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving JAZZ Today?
No stock-specific AI insight has been generated for JAZZ yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$97.56$230.40
$228.57
Fundamentals
Market Cap$14.3B
P/E Ratio2,077.9
EPS$0.11
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume2.1M
Avg Volume (10D)—
Shares Outstanding62.7M
JAZZ News
21 articles- Is It Time To Reevaluate Jazz Pharmaceuticals (JAZZ) After A 125% One Year Rally?Yahoo Finance·May 7, 2026
- ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 ExpressionYahoo Finance·May 7, 2026
- Jazz Pharmaceuticals Delivered Strong Q1 on Broad-Based Portfolio Growth, RBC SaysYahoo Finance·May 6, 2026
- JAZZ Stock Jumps as Q1 Earnings & Sales Surpass ExpectationsYahoo Finance·May 6, 2026
- Jazz Pharmaceuticals plc Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Jazz Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 6, 2026
- Jazz (JAZZ) Q1 2026 Earnings Call TranscriptMotley Fool·May 5, 2026
- Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top EstimatesYahoo Finance·May 5, 2026
- Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 SalesYahoo Finance·May 5, 2026
- Jazz Pharmaceuticals Announces First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity SalesYahoo Finance·May 5, 2026
- Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look ForYahoo Finance·May 4, 2026
- ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026Yahoo Finance·Apr 30, 2026
- How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment NarrativeYahoo Finance·Apr 27, 2026
- Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals StocksYahoo Finance·Apr 27, 2026
- Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEAYahoo Finance·Apr 27, 2026
- Barclays Raises its Price Target on Jazz Pharmaceuticals (JAZZ) to $225Yahoo Finance·Apr 24, 2026
- 3 Overrated Stocks with Warning SignsYahoo Finance·Apr 24, 2026
- Tuberous Sclerosis Complex Market Research and Global Long-term Forecast Report 2026-2035 Featuring Prominent Players - Novartis, Jazz Pharmaceuticals, Nobelpharma AmericaYahoo Finance·Apr 23, 2026
- Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightGlobeNewswire Inc.·Apr 20, 2026
All 21 articles loaded
Price Data
Open$227.88
Previous Close$212.26
Day High$230.40
Day Low$221.30
52 Week High$230.40
52 Week Low$97.56
52-Week Range
$97.56$230.40
$228.57
Fundamentals
Market Cap$14.3B
P/E Ratio2,077.9
EPS$0.11
Dividend Yield—
Dividend / Share—
ROE-0.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume2.1M
Avg Volume (10D)—
Shares Outstanding62.7M
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—